Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 山东威高骨科材料股份有限公司的主营业务为骨科医疗器械的研发、生产和销售,主要产品包括骨科植入医疗器械以及骨科手术器械。在骨科植入医疗器械领域,公司是国内产品种类齐全、规模领先、具有市场竞争力的企业之一。公司是国内首批进入高端植入骨科医疗器械领域的厂商之一,始终以技术和产品为导向,专注于骨科植入医疗器械的创新与研发,不断保持产品的更新迭代。目前公司拥有169项第I类、7项第II类、80项第III类医疗器械产品备案证或者注册证,产品线已全面覆盖脊柱、创伤、关节及运动医学等各骨科植入医疗器械细分领域,公司各类产品组合已充分应用于各类骨科疾病的治疗,有效满足了多样化的临床需求,是国内产品线最完善的骨科植入医疗器械厂商之一。多年以来,公司深耕骨科植入医疗器械领域,顺应行业发展趋势,充分把握了国产高端产品进口替代的历史机遇。目前公司产品主要以中高端骨科植入物为主,同时充分覆盖了经济型产品市场,已在全国范围内超过1,500家医院广泛应用。根据标点信息的相关研究报告,2019年度,公司在国内骨科植入医疗器械领域的整体市场份额位居国内厂商第一,全行业第五,各细分领域均排名靠前。其中,脊柱类产品市场份额位居国内厂商第一、全行业第三,创伤类产品市场份额位居国内厂商第二、全行业第五,关节类产品市场份额位居国内厂商第三、全行业第七。公司已经较好地实现了对部分外资企业的超越并快速拉近了与国际巨头之间的差距,具有领先的市场规模与行业地位。
Main Business 骨科医疗器械的研发、生产和销售
Legal Representative 陈敏
Top Executives
董事长：陈敏
董事：陈敏,孔建明,邬春晖,张瑞杰,龙经,卢均强
独立董事：贾彬,曲国霞,刘洪渭
Top 5 Shareholder
Shareholder name Nature Holding Date
山东威高集团医用高分子制品股份有限公司流通A股50.63%30/09/2024
威高國際醫療有限公司流通A股16.88%30/09/2024
威高集团有限公司流通A股7.50%30/09/2024
山东省财金投资集团有限公司流通A股6.31%30/09/2024
威海弘阳瑞信息技术中心（有限合伙）流通A股5.83%30/09/2024
Company Secretary 林青
Solicitors 北京市中伦律师事务所
Auditors 大华会计师事务所（特殊普通合伙）
Tel No 0631-5788909
Fax No 0631-5660958
Website www.wegortho.com
Email ir@wegortho.com
Company Address
Register: 山东省威海市旅游度假区香江街26号
Office: 山东省威海市旅游度假区香江街26号
Listing Date 30/06/2021
Shares Capital
Shares Capital: 400,000,000
Total A Share: 400,000,000
Listed A Share: 400,000,000
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.280
DPS(RMB)* ¥ 0.120
NBV Per Share(RMB)* ¥ 9.672
Market Capitalization(RMB) 10.792B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.